India has officially approved and launched Mounjaro (tirzepatide), a groundbreaking injectable medication for the treatment of Type 2 diabetes and obesity. Developed by Eli Lilly and Company, the drug ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Three dads share how their bodies and family relationships have changed since they began taking GLP-1 weight loss medications ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

BBB National Programs’ National Advertising Division reviewed a challenge brought by Eli Lilly and Company regarding express ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and ...

Lexaria Bioscience (LEXX) announced that human study GLP-1-H25-5 which compared oral capsules of DehydraTECH-liraglutide to ...